Glomerulonephritis, IGA  >>  blisibimod (A-623)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
blisibimod (A-623) / Anthera Pharma
NCT02052219: BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

Withdrawn
3
0
US
Blisibimod, Placebo
Anthera Pharmaceuticals
IgA Nephropathy
10/16
10/21
BRIGHT-SC, NCT02062684 / 2014-001365-26: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

Hourglass Dec 2016 - Mar 2017 : for the treatment of IgA Nephropathy
Hourglass Dec 2016 - Mar 2017 : for the treatment of IgA Nephropathy
Checkmark Interim analysis for the treatment of lupus nephritis
Jun 2016 - Jun 2016: Interim analysis for the treatment of lupus nephritis
Completed
2/3
57
Europe, RoW
Blisibimod, Placebo
Anthera Pharmaceuticals
IgA Nephropathy
03/17
06/17

Download Options